IRIS
MONDELLI, MARIO UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.802
AS - Asia 8.261
EU - Europa 6.904
SA - Sud America 1.261
Continente sconosciuto - Info sul continente non disponibili 559
AF - Africa 259
OC - Oceania 18
AN - Antartide 1
Totale 31.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.241
CN - Cina 3.992
SG - Singapore 1.808
IE - Irlanda 1.390
BR - Brasile 942
UA - Ucraina 889
IT - Italia 888
HK - Hong Kong 884
DE - Germania 807
FI - Finlandia 731
VN - Vietnam 711
RU - Federazione Russa 686
FR - Francia 462
SE - Svezia 382
GB - Regno Unito 364
CA - Canada 253
IN - India 158
BD - Bangladesh 155
AR - Argentina 108
ZA - Sudafrica 85
IQ - Iraq 69
JP - Giappone 64
MX - Messico 64
EC - Ecuador 56
ID - Indonesia 53
CO - Colombia 45
PL - Polonia 45
NL - Olanda 44
TR - Turchia 41
IL - Israele 40
ES - Italia 39
VE - Venezuela 36
CR - Costa Rica 35
PK - Pakistan 35
AT - Austria 32
TT - Trinidad e Tobago 31
NI - Nicaragua 30
HN - Honduras 29
MA - Marocco 28
SA - Arabia Saudita 28
GT - Guatemala 27
CZ - Repubblica Ceca 26
UZ - Uzbekistan 26
SV - El Salvador 24
GP - Guadalupe 22
SC - Seychelles 22
CL - Cile 21
TN - Tunisia 20
DZ - Algeria 19
PR - Porto Rico 19
BE - Belgio 18
KE - Kenya 18
PH - Filippine 18
EG - Egitto 17
PY - Paraguay 17
IR - Iran 15
KZ - Kazakistan 15
MY - Malesia 15
CW - ???statistics.table.value.countryCode.CW??? 14
JM - Giamaica 14
AU - Australia 13
JO - Giordania 13
NP - Nepal 13
AZ - Azerbaigian 12
CH - Svizzera 12
PE - Perù 12
UY - Uruguay 12
KG - Kirghizistan 11
EE - Estonia 10
LT - Lituania 10
TH - Thailandia 10
BH - Bahrain 9
OM - Oman 9
KR - Corea 8
AE - Emirati Arabi Uniti 7
BO - Bolivia 7
GA - Gabon 7
GR - Grecia 7
AL - Albania 6
BG - Bulgaria 6
EU - Europa 6
LB - Libano 6
SN - Senegal 6
AM - Armenia 5
BB - Barbados 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HR - Croazia 5
PS - Palestinian Territory 5
RO - Romania 5
CI - Costa d'Avorio 4
HU - Ungheria 4
KW - Kuwait 4
LV - Lettonia 4
MU - Mauritius 4
QA - Qatar 4
SI - Slovenia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
Totale 30.453
Salva come PNG Salva come JPEG
Città #
Chandler 1.439
Ashburn 1.404
Dublin 1.386
San Jose 1.261
Jacksonville 1.195
Singapore 914
Nanjing 904
Hong Kong 871
Council Bluffs 835
Dallas 745
Beijing 527
Boardman 488
Nanchang 380
Princeton 328
Lawrence 289
Lauterbourg 284
Wilmington 273
Shenyang 254
Hebei 237
Los Angeles 235
Changsha 231
Ho Chi Minh City 221
Jiaxing 220
Milan 190
Helsinki 186
Tianjin 174
New York 163
Medford 161
Hanoi 160
Munich 156
Hangzhou 139
Buffalo 128
Santa Clara 126
Redondo Beach 122
Moscow 120
Ann Arbor 99
Shanghai 96
São Paulo 90
Toronto 89
Pavia 79
Verona 71
Orem 69
Tokyo 61
Turku 60
Woodbridge 60
Johannesburg 59
Norwalk 59
Chicago 55
Seattle 54
Brooklyn 51
Montreal 46
Da Nang 42
Rome 42
Columbus 38
The Dalles 37
Houston 36
Warsaw 36
Frankfurt am Main 35
Denver 33
Zhengzhou 33
Baghdad 31
Chennai 31
Nuremberg 31
Phoenix 31
San Francisco 31
Des Moines 30
Guangzhou 30
Jinan 30
Haiphong 29
Managua 29
Quito 27
Rio de Janeiro 27
Fairfield 26
London 26
Atlanta 24
Boston 24
North Bergen 24
San José 24
Brasília 23
Charlotte 23
Falkenstein 23
Tashkent 23
Dong Ket 22
Manchester 22
San Salvador 21
Falls Church 20
Pune 20
Auburn Hills 19
Curitiba 19
Guatemala City 19
Kunming 19
Naples 19
Newark 19
Turin 19
Washington 19
Amsterdam 18
Las Vegas 18
Stockholm 18
Belo Horizonte 17
Brussels 17
Totale 19.118
Salva come PNG Salva come JPEG
Nome #
MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma 323
Mapping the human genetic architecture of COVID-19 317
A first update on mapping the human genetic architecture of COVID-19 232
Mapping the human genetic architecture of COVID-19 211
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 164
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 160
Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy 159
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 158
Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020 148
Cross-reactive antibodies to hypervariable region 1 (HVR1) of the hepatitis C virus E2/gp70 glycoprotein 146
Development, Expansion, and Histological Characterization of Patient-Derived Liver Organoids for Drug Screening and Disease Modeling 144
Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs 143
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 138
Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre 136
Antibody responses to the hepatitis C virus (HCV) E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. 132
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 131
CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. 130
Comparative evaluation of two serological typing methods for hepatitis C virus 130
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 130
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma 129
A major conformational B cell epitope on the HCV NS3 region defined by a human monoclonal antibody 128
Alfa-interferon enhances non-T cell cytotoxicity fo rautologous hepatocytes in acute and chronic HBV infection 127
A longitudinal analysis of hepatitis C virus replication following liver transplantation 127
Adenoviral mediated expression of anti-HCV NS3 single-chain Fv (sFv) antibody reduces HCV RNA in infected hepatocytes 127
COVID vaccination and asthma exacerbation: might there be a link? 127
Low prevalence of antibodies to the HCV envelope region in anti-HCV seronegative, HCV RNA positive patients 126
Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing? 126
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 126
Acute hepatitis C: diagnosis and management. 125
Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. 124
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 124
Codon 72 polymorphisms of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients 123
Detection of HTLV-III specific IgG in the CSF from patient with AIDS and encephalitis. 123
A survey of hepatitis C virus infection in haemodialysis patients over a 7-years follow-up. 123
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 123
Characterization of monoclonal antibodies (mAb) from mice immunized with HCV hypervariable region 1 (HVR1) mimotopes. 122
Immunophatogenesis of viral hepatitis 122
Hepatitis B virus structure and biology. 121
A phase II, single arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 120
Recombinant human antibodies specific for hepatitis C virus proteins 120
Accuracy of the ElastPQ Technique for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C: a "Real Life" Single Center Study 120
Clinical significance of hepatitis C virus genotypes. 119
Molecular epidemiology of hepatitis C virus infection in intravenous drug users. 119
Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre 119
Antibody-negative chronic hepatitis C virus infection in immunocompetent children 118
Defective cytotoxic function of intrahepatic natural killer cells in chronic hepatitis C virus infection 118
Absence of antibodies to human immunodeficiency virus in long-term institutionalized psychiatric patients. 118
Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation 116
A human monoclonal antibody specific for a conserved epitope within the HCV protein 116
GB virus C infection in patients treated for childhood acute lymphoblastic leukemia 116
HCV viremia in hemodialysis patients 116
Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes 116
High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders 116
Does the immune response play a role in the pathogenesis of chronic liver disease? 115
Optimization for the detection of hepatitis C virus (HCV) antigens in the liver 115
Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis 115
NKG2D and its ligands: key to immunotherapy of liver cancer? 114
Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. 114
Analysis of hepatitis C virus hypervariable region 1 sequence in cryoglobulinaemic patients and associated control 114
A human monoclonal antibody specific for the N-terminus of hepatitis C virus nucleocapsid protein 113
Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications 113
Comparative evaluation of two serologic typing methods of hepatitis C virus 113
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. 112
Dissociation between serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus 112
Association between class II allelles and protection or susceptibility to chronic hepatitis C 112
B lymphocyte activation in chronic HCV infection: implications for autoimmune and lymphoproliferative disorders 111
ANTIBODY RESPONSES TO HEPATITIS C VIRUS HYPERVARIABLE REGION 1: EVIDENCE FOR CROSS-REACTIVITY AND IMMUNE-MEDIATED SEQUENCE VARIATION. 111
Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56brightNK cells 111
Impaired intratumoral natural killer cell function in head and neck carcinoma 110
Genetic mechanisms of critical illness in COVID-19 110
Polymorphisms of microsomal epoxyde hydrolase gene and severity of HCV-related liver disease. 109
A human antibody specific for the hepatitis C virus core protein: expression in a bacterial system and characterization. 109
PD-L1 negatively regulates CD4+CD25+Foxp3+ tregs by limiting STAT-5 phosphrylation in patients chronically infected with HCV 109
Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST expert opinion meeting 108
The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort 108
Is the natural history of hepatitis C virus carriers with normal aminotransferase really bening? 107
Identification of an immunodominant B-cell epitope on the NS4 subregion of HCV defined by human monoclonal antibodies. 107
HCV genotype 1b is a major risk factor for the development of hepatocellular carcinoma (HCC) in cirrhotic patients: a prospective study 107
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 107
Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells 106
HLA class II alleles confer protection or susceptibility to chronic hepatitis C 106
SIGNIFICANCE OF THE IMMUNE RESPONSE TO A MAJOR, CONFORMATIONAL B CELL EPITOPE ON THE HEPATITIS C VIRUS NS3 REGION DEFINED BY A HUMAN MONOCLONAL ANTIBODY 106
A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity 106
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy 106
Modelling liver fibrosis progression in chronic hepatitis C: a study of 563 patients with sequential liver biopsies 105
Characterization of cryoglobulins from patients with type II mixed cryoglobulinaemia associated with HCV 105
T-cell cytotoxicity and circulating T-cell subsets in chronic HBV infection 105
Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C 104
Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. 104
Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not rescricted to patients with cryoglobulinemia 103
Viral and host immune regulatory mechanisms in HCV infection 103
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. 103
Detection of genomic and minus strand C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative RT-PCR 103
The impact of viral genotype on the natural history of HCV-induced cirrhosis: a prospective study 103
EASL Clinical Practice Guidelines: management of hepatitis C virus infection 103
Optimization for the detection of hepatitis C viral (HCV) antigens in liver. 103
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 103
Hypervariable region 1 (HVR1) of HCV: immunological decoy or biologically relevant domain? 102
Polymorphisms of microsomal epoxyde hydrolase gene and severity of HCV-related liver disease. 101
Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. 101
Totale 12.439
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.450
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.450
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.073 0 0 0 0 16 71 12 83 70 25 197 599
2022/20234.267 515 232 30 468 432 453 2 225 1.648 16 201 45
2023/20241.683 150 246 46 116 162 375 47 363 7 40 53 78
2024/20253.924 90 398 133 162 61 114 179 290 947 103 427 1.020
2025/20269.084 683 803 1.139 1.056 963 374 1.656 336 786 678 338 272
2026/20273.545 222 571 724 1.300 728 0 0 0 0 0 0 0
Totale 31.065